High-resolution genomic analysis and whole exome sequencing studies identified extremely low mutation rates for genes other than the biallelic inactivation of SMARCB1 in rhabdoid tumors [5, 7]. This evidence concerns the gene SMARCB1 and rhabdoid tumor.